Pipeline
We are building a robust pipeline of blood-based diagnostic tests to transform the standard of care in a range of diseases
Validated Potential in Neurological Diseases and Early-Stage Cancers
Our APEX and Glympse technologies have demonstrated potential to improve upon gold-standard diagnostic tests in multiple disease areas beyond Alzheimer’s. We are currently partnering with biopharma companies and researchers to bring to market the broadest panel of neurological disorder and cancer diagnostics that empower researchers and clinicians with unparalleled insights not readily available from current tests across therapeutic areas.
BIOMARKER
INDICATION
Neurology
Amyloid beta (Aβ)
Tau
Alpha synuclein (α-synuclein)
TDP-43
Proprietary proteins (undisclosed)
Alzheimer’s disease
Alzheimer's disease, Tauopathies
Alzheimer’s disease, Parkinson's disease, Synucleinopathies
Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Frontotemporal dementia (FTD)
Amyloid-related imaging abnormalities (ARIA), Brain vascular damage
Oncology
Proprietary proteases (undisclosed)
Colon cancer / colorectal polyps
APEX: The APEX platform offers versatility to directly identify protein biomarkers from the brain – using a simple blood test – across multiple disease indications beyond Alzheimer’s disease, including Parkinson’s disease, multiple sclerosis, glioblastoma, pancreatic cancer and heart disease. These biomarkers include both aggregated (i.e., sticky) proteins known to signify the presence of disease, and markers carried on extracellular vesicles (EVs), such as amyloid beta (Aβ), tau, alpha synuclein (α-synuclein), and other protein and non-protein biomarkers.
Glympse: Due to its novel ability to measure and analyze protease activity in the blood, the Glympse platform could provide actionable insights for the many diseases, including cancers, that have altered protease activity from the earliest stages. Given strong scientific evidence suggesting that distinct changes in protease activity also occur as diseases progress (e.g., stages 1-4 of cancers), Glympse also has potential to support precise disease monitoring.
Initial data from a preclinical study using the Glympse platform in hepatocellular carcinoma (HCC) demonstrated diagnostic potential for protease activity. It also provided proof of concept for the platform, which effectively differentiated between subjects with HCC and healthy controls in all cohorts.